Antibiotic selection in 90–120 minutes, not days
In sepsis, the most important decision is selecting the right antibiotic. That decision must be made within the first 1–2 hours.
The current standard—culture and antimicrobial susceptibility testing (AST)—provides the correct answer, but arrives 3–5 days too late. During this gap, treatment is empirical, broad-spectrum antibiotics are used, ineffective therapy may be given, and escalation is delayed.
The limitation is not accuracy. It is timing.
Guanine resolves this directly. It enables definitive antibiotic selection within 90–120 minutes by measuring what is present and what responds to treatment within the same clinical window.
Culture provides truth—but too late for decision-making
Culture and AST remain the clinical reference standard because they measure functional susceptibility. But they do not operate within the decision window that matters most in sepsis.
Faster molecular tests improve time to identification, but they do not confirm which therapy actually works. As a result, clinicians still choose treatment before definitive data is available.
| Dimension | Culture / AST | Guanine |
|---|---|---|
| Core Output | Functional susceptibility after organism growth | Functional susceptibility plus genotype within the clinical window |
| Timing | 3–5 days | 60–120 minutes depending on measurement layer |
| Pathogen Identification | Delayed and growth-dependent | Direct pathogen and resistance profiling in ≈60 minutes |
| Susceptibility | Definitive but delayed | Direct phenotypic response in ≈90–120 minutes |
| Workflow | Sequential, laboratory-based, technician-intensive | Integrated cartridge workflow with near-patient potential |
| Treatment Usefulness | Often arrives after empirical therapy decisions are already made | Designed to inform the initial treatment decision |
Measuring response directly, not waiting for growth
Culture determines susceptibility by observing organism growth over time. Guanine measures biological response directly.
Organisms are exposed to antibiotics in-cartridge, response is monitored continuously, and susceptibility is determined from real-time signal changes. This preserves functional truth while eliminating growth-dependent delay.
Continuous phenotypic measurement enables treatment response to be determined within the initial decision window.
Parallel genotype and phenotype for treatment selection
Guanine collapses the delay between identification and susceptibility by running two complementary measurements in parallel.
Genotype answers what is present.
Phenotype answers what responds to treatment.
Together, they produce a closed-loop answer within the same clinical window.
Genotype (≈60 minutes)
Broad pathogen detection across bacteria, viruses, fungi, and protozoa, with resistance gene profiling and quantitative pathogen burden.
Phenotype (≈90–120 minutes)
Direct measurement of antibiotic response, growth inhibition, and kill kinetics across multiple doses.
Combined System Outcome
Identification narrows candidates, phenotyping confirms effective therapy, and discordance between genotype and response is resolved immediately.
Closed-loop treatment selection
This is not just faster identification. It is a system that connects detection and treatment confirmation within a single diagnostic window.
Result: antibiotic selection based on measured response, not inference.
No blind spots in early detection
Sepsis can be caused by atypical bacteria, viruses, fungi, and protozoa that are not detected by cultures. Guanine provides a quantitative test that measures the top ~50 sepsis-causing pathogens and key resistance genes in 60 minutes.
Phenotyping is inherently selective and optimized for common, fast- and moderate-growing pathogens.
Genotype expands coverage to atypical pathogens, slow-growing organisms, non-culturable organisms, and viral and fungal contributors.
Running both in parallel creates a closed decision loop:
- Genotype identifies candidates and burden early
- Phenotype confirms actual response
- Cross-validation resolves discrepancies
| Coverage Beyond the Phenotyping Panel = Combined System Insight | ||
|---|---|---|
| Approach | Strength | Limitation |
| Genotype | Fast, broad detection | Cannot confirm functional susceptibility |
| Phenotype | True functional response | Limited organism scope, slower |
Sepsis diagnosis is fragmented today. Guanine aligns host response, pathogen identification, and functional susceptibility to the timing of treatment decisions.
Time-aligned measurement model
Host response panel for early rule-in / rule-out, triage, and escalation context.
Genotype cartridge for pathogen identity, resistance markers, and pathogen burden.
Phenotype cartridge for direct antibiotic response and definitive treatment selection.
The First Decision: Is This Sepsis?
Before selecting therapy, clinicians must determine whether sepsis is present. Current tools rely on non-specific scores, limited biomarkers, and weakly quantitative inputs.
Guanine adds a rapid host response panel to improve early context:
- Multi-marker inflammatory profile
- Quantitative measurement of key cytokines and proteins
- Rapid turnaround
- Context for downstream genotype and phenotype results
Test results fulfill a critical clinical role:
- Early rule-in / rule-out
- Triage and escalation
- Context for downstream genotype + phenotype
The host response panel:
- does not replace the core system
- does not define the breakthrough
It provides:
→ early context before definitive treatment selection
Earlier, more precise therapy selection
The shift is fundamental: from delayed confirmation to real-time treatment guidance.
Earlier appropriate antibiotic selection
Treatment is selected based on measured response, not probability alone.
Reduced ICU and hospital stay
Faster optimization reduces deterioration, escalation, and downstream resource utilization.
Lower cost per patient
Shorter stays and fewer complications reduce total cost of care.
Reduced mortality risk
Earlier effective treatment is linked directly to improved outcomes in sepsis.
From delayed confirmation to real-time treatment selection
The standard of care was built around what could be measured—not when decisions are made.
Guanine aligns measurement with decision timing by connecting early context, pathogen identity, and functional susceptibility into a single system.
This is not a faster test. It is a system for selecting the right treatment within the clinical decision window.
Sepsis Diagnosis at the Speed of Clinical Decision
Time-aligned diagnostics delivering actionable insight across the first critical hours of sepsis—plus upcoming product configurations.
